化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
结合了CPA的AR可与核受体协同抑制因子作用。
第一信号为抗原与T细胞受体TCR的结合，第二信号为抗原递呈细胞上的协同刺激分子与T、B淋巴细胞上的受体结合。
The first signal is the binding of antigen with TCR on T cells. The second signal is the binding of co-stimulate on the APC with their receptors presenting on T and B lymphocytes.
第一信号为抗原与T细胞受体TCR的结合，第二信号为抗原递呈细胞上的协同刺激分子与T、B淋巴细胞上的受体结合。
The first signal is the binding of antigen with TCR on T cells. The second signal is the binding of co-stimulate on the APC with their receptors presenting on T and B lymphocytes.
应用推荐